Last updated: 2026-10-13 23:15:00. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Achieve Life Sciences, Inc. (ACHV) operates in the IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES sector and is listed on NASDAQ. The stock is currently priced at $7.01, with a market capitalisation of $763.99M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $2.62 to $8.64. This page covers its latest market performance, valuation, price trends and company information.
$763.99M | |
$7.00 | |
$970.00 | |
$1.84 | |
$7.06 | |
1.46M | |
1.40M | |
-- | |
$8.64 | |
$2.62 | |
-- | |
-- |
Achieve Life Sciences, Inc. (ACHV) is trading at $7.01 in after-hours trading as of 2026-10-13 21:30:00, down 0.78% ($0.05) from the regular-session close of $7.06.
After-hours trading shows how investors are pricing ACHV after the regular session closes. The current after-hours price is below the regular-session close, indicating cautious after-hours sentiment.
Over the past seven days, Achieve Life Sciences, Inc. (ACHV) moved from $7.24 to $7.01, representing a decline of 3.25% ($0.24).
The stock traded between $6.83 and $7.63 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 1.25 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 72.8%
ACHV is currently trading at $7.01, placing it 72.8% of the way from its 52-week low of $2.62 to its 52-week high of $8.64. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K.
| Industry | IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES |
| Employees | 28 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Achieve Life Sciences, Inc. (ACHV) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.